SCHEMBL21585683

SCHEMBL21585683

COc1cc(O)cc2c1CC(O)C(c1cc(O)c(O)c(O)c1)O2

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 6/20 0.71
PTGS1 P23219 5/20 0.71
KDM4E B2RXH2 4/20 0.71
SNCA P37840 3/20 0.71
ALDH1A1 P00352 3/20 0.71
MAPT P10636 3/20 0.71
APEX1 P27695 3/20 0.71
RECQL P46063 3/20 0.71
HSD17B10 Q99714 3/20 0.71
HPGD P15428 2/20 0.71
ALOX15 P16050 2/20 0.71
TDP1 Q9NUW8 2/20 0.71
RAD52 P43351 2/20 0.71
CNR1 P21554 1/20 0.71
MAPK14 Q16539 1/20 0.67
ABCB1 P08183 2/20 0.59
CYP3A4 P08684 2/20 0.57
MAPK1 P28482 2/20 0.57
SYNJ2 O15056 2/20 0.55
MMP2 P08253 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13099977 1.00 BACE1 (0.71) BACE1PTGS1KDM4ESNCAALDH1A1
SCHEMBL862117 0.89 BACE1 (0.63) BACE1PTGS1KDM4ESNCAALDH1A1
SCHEMBL26481134 0.89 BACE1 (0.59) BACE1PTGS1KDM4ESNCAALDH1A1
SCHEMBL21586653 0.89 ABCB1 (0.76) BACE1PTGS1KDM4ESNCAALDH1A1
SCHEMBL13099973 0.89 BACE1 (0.78) BACE1PTGS1KDM4ESNCAALDH1A1
SCHEMBL13099978 0.88 KDM4E (0.73) BACE1PTGS1KDM4ESNCAALDH1A1
SCHEMBL862191 0.88 KDM4E (0.73) BACE1PTGS1KDM4ESNCAALDH1A1
SCHEMBL862110 0.85 BACE1 (0.62) BACE1PTGS1KDM4ESNCAALDH1A1
SCHEMBL1974812 0.85 BACE1 (0.62) BACE1PTGS1KDM4ESNCAALDH1A1
Epigallocatechin SCHEMBL1972938 0.84 BACE1 (1.00) BACE1PTGS1KDM4ESNCAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11643405-B2 Compound for treatment or prevention of liver diseases JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2023-05-09 US disclosed
US-11643405-B2 Compound for treatment or prevention of liver diseases JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2023-05-09 US disclosed
US-11643405-B2 Compound for treatment or prevention of liver diseases JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2023-05-09 US disclosed
CN-110183431-B Compound for treating or preventing liver diseases 江苏新元素医药科技有限公司 2023-04-11 CN disclosed
US-20210246126-A1 COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2021-08-12 US disclosed
US-20210246126-A1 COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2021-08-12 US disclosed
EP-3805216-A1 COMPOUNDS FOR TREATMENT OR PREVENTION OF LIVER DISEASES Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. (CN) 2021-04-14 EP disclosed
EP-3805216-A1 COMPOUNDS FOR TREATMENT OR PREVENTION OF LIVER DISEASES Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. (CN) 2021-04-14 EP disclosed
WO-2019233440-A1 COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES 江苏新元素医药科技有限公司 (CN) 2019-12-12 WO disclosed
WO-2019233440-A1 COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES 江苏新元素医药科技有限公司 (CN) 2019-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210246126-A1 COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES SLC10A1, GYS2, CPT1A BACE1 1906/4885PTGS1 342/4885KDM4E 4649/4885
US-11643405-B2 Compound for treatment or prevention of liver diseases SLC10A1, GYS2, CPT1A BACE1 1906/4885PTGS1 342/4885KDM4E 4649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.